The impact of HIV coinfection on mpox patients: a systematic review and meta-analysis Authors: Lei Ji, Defu Yuan, Fuchun Wang, Wenya Hong, Zhen Li, Taiyi Jiang, Bin Su Published: 2026 ABSTRACT ABSTRACTA substantial proportion of mpox cases occur in people with HIV, but how HIV coinfection and immune status affect clinical outcomes remains unclear. We systematically searched major databases up to March 2025 for observational studies comparing mpox patients with and without HIV coinfection. Pooled effect sizes were calculated using random-effects models. Risk ratios (RRs) or standardized mean differences (SMDs) with 95% confidence intervals were used for dichotomous or continuous outcomes. Post hoc subgroup analyses explored differences by economic development, viral suppression, and advanced HIV disease (AHD) proportion. Among 15,522 patients from 29 studies, 52.43% had HIV. HIV coinfection was associated with higher hospitalization [RR = 1.50, 95% CI (1.17, 1.93)] and mortality [RR = 4.54, 95% CI (2.11, 9.77)]. Coinfected patients had more syphilis, HBV, and HCV coinfections, and higher rates of fever, proctitis, malaise, rectal irritation syndrome, diarrhoea, skin and soft tissue infections, and pneumonia. Blood tests showed lower albumin, calcium, and haemoglobin, and higher CK-MB. Perianal lesions were more common with HIV. HIV coinfection is linked to greater clinical severity, mortality, and STI coinfections. Exploratory analyses suggest poor viral suppression may drive adverse outcomes, and lesion severity relates to immune status. All subgroup findings are post hoc and hypothesis-generating, limited by aggregate data. Intensified monitoring and supportive care, vaccination, and optimized ART initiation are crucial for this population.KEYWORDS: MPXV, HIV coinfection, clinical features, hospitalization, mortality, sexually transmitted infections (STIs) Background Mpox is a zoonotic infectious disease caused by the mpox virus (MPXV). The WHO declared the mpox outbreak a Public Health Emergency of International Concern (PHEIC) in 2022 and again in 2024, issuing a global alert [1]. Since 2022, nearly 180,000 confirmed mpox cases have been reported from 144 countries [2]. MPXV belongs to the orthopoxvirus genus of the family Poxviridae; is closely related to vaccinia virus, variola virus, and cowpox virus; and can be divided primarily into Central African and West African clades [3]. The incubation period for MPXV infection is 7–21 days. Nonspecific clinical symptoms include headache, fever, and lymphadenopathy. Characteristic skin lesions typically progress through stages of macules, papules, vesicles, pustules, and crusts, which can be present simultaneously. In men infected via sexual contact, the rash is predominantly located in the anogenital region [4]. Although MPXV infection is often self-limiting, severe immunosuppression is a significant risk factor for more severe disease and even death [5,6]. In mpox patients with immune dysfunction, infection can still trigger a strong nonspecific immune response at the local lesion site, but the ability of the body to control viral replication and clear infected cells is markedly reduced [7]. Notably, HIV and MPXV exhibit a high rate of coinfection, a pattern that is particularly prominent among men who have sex with men (MSM) [8]. HIV primarily infects CD4+ T cells, leading to their progressive decline and severe functional impairment, resulting in defective immune responses and dysregulation of immune coordination mechanisms [9]. Antiretroviral therapy (ART) cannot fully reverse the resulting immunopathological damage, and immune function recovery is often incomplete [10]. Severe immune suppression is a significant risk factor for prolonged disease duration, more complex and severe clinical manifestations, and higher mortality in mpox patients [11]. However, the precise effects of HIV coinfection on key clinical outcomes in mpox patients, including hospitalization rates, mortality, sexually transmitted coinfections, clinical manifestations, skin lesion characteristics, and biochemical markers, remain incompletely characterized. In particular, whether these outcomes differ according to the level of HIV viral control is poorly defined. In the absence of specific anti-MPXV drugs, summarizing and analysing the impact of HIV coinfection on mpox patients is crucial for informing the development of clinical guidelines [12]. This meta-analysis synthesizes available observational studies published since the onset of the mpox outbreak, combining data on hospitalization, death, coinfection with sexually transmitted pathogens, clinical features, skin lesions, and blood test results among mpox patients. HIV infection was used as the exposure factor to compare differences between the exposed and control groups. When the data were available, exploratory subgroup analyses were performed stratifying the data by economic development level, HIV viral suppression status, and the proportion of participants with advanced HIV disease (AHD). This work aims to clarify the effects of HIV coinfection on mpox patients and provide a reference for guiding clinical management. Methods Registration This meta-analysis was registered with PROSPERO (https://www.crd.york.ac.uk/PROSPERO, ID: CRD420251021372). It was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement [13]. Search strategy Searches were performed in PubMed, Cochrane, EMBASE, and Web of Science for original studies investigating the impact of HIV on MPXV infection. The search time frame ranged from database inception to March 2025. The search strategy included terms for HIV (Acquired Immune Deficiency Syndrome Virus; Human Immunodeficiency Virus) and MPXV (Monkey Orthopox Virus; Monkey Pox Virus). The detailed search strategy is provided in Table S1. Inclusion and exclusion criteria On the basis of the patient, exposure, comparison, outcome, and study design (PECOS) framework, the inclusion criteria were as follows: (1) participants: mpox patients; (2) exposure and comparison: exposed group: mpox patients coinfected with HIV; control group: mpox patients who were HIV-negative; (3) outcomes: the outcomes of interest were hospitalization rate, mortality, proportion of patients coinfected with other sexually transmitted pathogens, clinical features, skin lesion characteristics (location, morphology, number), and blood test results; and (4) study design: observational studies. The exclusion criteria were as follows: (1) case reports, animal studies, reviews, guidelines, expert consensus opinions, preprints, editorials, and conference abstracts were excluded to maintain evidence quality; (2) incomplete data: studies for which the full text was unavailable or those that did not report any of our specified outcomes; and (3) for the hospitalization outcome specifically, studies that enrolled only hospitalized patients or no patients with hospitalization events were excluded. This meta-analysis included only literature published in English. Literature screening and data extraction Two researchers independently screened the retrieved records using predefined inclusion and exclusion criteria. The initial search results were imported. Two authors independently screened the titles and abstracts to identify potentially eligible records. The full texts of these potentially eligible publications were then reviewed against the inclusion and exclusion criteria. The references of all included studies were also screened for additional eligible studies. Two reviewers independently extracted data from each study using a prespecified data extraction form. Disagreements between reviewers were resolved through consultation with a third reviewer. For each publication, the following information was extracted: first author’s name, cohort year, study location and period, sample size with HIV coinfection, and outcome measures (hospitalization rate, mortality, proportion with other STIs, clinical features, skin lesion characteristics, and blood test results). If the data were presented only graphically, the graphic digitization software Engauge Digitizer (version 12.1; https://markummitchell.github.io/engauge-digitizer/) was used to digitize and extract the numerical values. Quality assessment Two researchers independently assessed study quality by reading the full texts. Case–control and cohort studies were evaluated using the Newcastle-Ottawa Scale (NOS) [14]. The NOS assesses three domains: selection of study groups, comparability of groups, and ascertainment of either the exposure or the outcome. The quality is classified on the basis of scores: high quality (≥ 7), moderate quality (4–6) and low quality (< 4). Cross-sectional studies were assessed using the Joanna Briggs Institute (JBI) critical appraisal tool to determine eligibility for inclusion [15]. Statistical analysis Data synthesis and statistical analysis Data synthesis and statistical analyses were performed using R 4.4.2. Given the methodological diversity across studies and the expected variation in regional population characteristics and healthcare conditions, true between-study differences in effect sizes cannot be dismissed. Accordingly, a random-effects model was prespecified as the primary analytical approach for all meta-analyses. The I² statistic was reported to describe the extent of between-study heterogeneity, but the I² value was not used as a threshold for model selection. For dichotomous outcomes, effect sizes were expressed as risk ratios (RRs) with 95% confidence intervals; for continuous outcomes, standardized mean differences (SMDs) were used. A P value < 0.05 was considered to indicate statistical significance. Forest plots were used to display the pooled results. Exploratory post hoc subgroup analyses All subgroup analyses in this study were post hoc and exploratory, and the results were intended only for hypothesis generation and not for confirmatory conclusions. (1) Economic development level: After the literature search and study selection were completed, we observed that the included studies originated from regions with substantial differences in economic development and hypothesized that this variation might be a major source of between-study heterogeneity. To explore this possibility, we conducted a post hoc, exploratory subgroup analysis based on the economic development level of the country in which each study was conducted (developing vs. advanced economies) [16]. (2) HIV viral suppression and CD4+ T-cell count: Two separate post hoc subgroup analyses were conducted using study-level aggregate data. Viral suppression: We extracted the proportion of participants per study who had achieved viral suppression (HIV RNA < 200 copies/mL or undetectable) and grouped studies with proportions of < 95% or ≥ 95% [17,18]. Advanced HIV disease (AHD): We extracted the proportion of participants per study with a CD4+ T-cell count < 200 cells/μL and grouped studies with proportions ≤ 5% or > 5% [19–21]. Only studies with ≥ 90% completeness for the relevant variable were included. The two indicators were analysed in separate univariate subgroup analyses, without cross-stratification. For outcomes ≥ 2 subgroup analyses, the Benjamini-Hochberg false discovery rate (FDR) procedure was applied within each outcome family to account for multiplicity. Subgroup interaction P values were extracted from meta-regression models (or from subgroup comparisons using the Q-test for interaction), and adjusted P values (q values) were calculated to control the expected proportion of false positives among all significant results. Raw and adjusted P values are reported for all subgroup analyses subject to correction. Subgroup signals with an adjusted P < 0.05 were considered robust to multiplicity; otherwise, they were interpreted as exploratory. For outcomes with only a single subgroup analysis, no multiplicity correction was applied. Assessment of publication bias and sensitivity analysis The approach to assessing publication bias was determined by the number of available studies per outcome, which is consistent with the recommendation of the Cochrane Handbook that funnel-plot-asymmetry tests should be performed only when at least ten studies are included [22]. For outcomes with fewer than ten studies, we did not perform formal statistical tests; instead, we qualitatively assessed potential small-study effects by visually inspecting the distribution of effect estimates in relation to study size. Given these limitations, we did not assert the “absence of publication bias” for any analysis. Sensitivity analysis was performed by sequentially excluding each study to check the robustness of the pooled results. Results Characteristics of the included studies This meta-analysis across four databases yielded a total of 1,879 articles. After screening according to the inclusion and exclusion criteria, 29 articles were ultimately included (Figure 1). The studies were conducted in 12 different countries: 14 in advanced economies and 14 in developing economies, and one was a multicentre cohort study involving 15 sites. A total of 15,522 patients were included, 94.54% of whom were male at birth, and 52.43% of whom were coinfected with HIV (Table 1). Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart. Table 1.Characteristics of included studies.StudyClass.Cohort yearCountryStudy designSample Size (n)AgeMale (n)HIV+(n)AHD (%)Viral suppression (%)Yang H. [23]De.2023Chinacohort4130.0 (26.0, 34.0)412114.3%95.0%Estévez S. [24]Ad.2022Spaincohort10033.0 (30.0, 42.0)9771/94.4%Silva MST. [25]De.2022Brazilcohort40933.0 (28.0, 40.0)3862135.7%84.9%Betancort-Plata C. [26]Ad.2022Spaincohort4240.0 (35.0, 51.0)42270.00%96.3%Costa AF. [27]De.2022Brazilcross-sectional309/309168/72.3%Angelo KM. [28]Mul.2022Mul.cross-sectional22637.0 (32.0, 43.0)22692/91.6%McLean J. [29]Ad.2022UScohort15435.0 (30.0, 42.0)154725.6%80.6%Hoffmann C. [30]Ad.2022Germancohort54639.0 [20.0–67.0]546256/95.8%Faherty EAG. [31]Ad.2022–23UScohort112434.0 (29.0, 42.0)1106487//Yinka-Ogunleye A. [32]De.2017–19Nigeriacase-control8631.0 (27.0, 38.0)6124//Kowalski J. [33]De.2022Polandcohort9433.0 (28.0, 38.0)94430.0%88.4%Caria J. [34]Ad.2022Portugalcross-sectional4137.2 ± 8.340250.0%88.0%Ramirez-Soto MC. [35]De.2022–23Perucross-sectional3561[25.0–58.0]34332123//Moraes-Cardoso I. [36]Ad.2022Spaincohort3333.0 (28.0, 43.0)3314//Li J. [37]De.2023Chinacohort4433.0 (19.0, 54.0)4427//Zhao B. [38]De.2023Chinacross-sectional5631.5 [19.0–51.0]5623//Mauas R. [39]De.2022–23Argentinacohort24736.0 (30.0, 42.0)2421822.2%78.6%Chastain DB. [40]Ad.2022UScohort322/29193//Pilkington V. [41]Ad.2022UKcohort15036.0 (30.0, 43.0)14958//Curran KG. [42]Ad.2022UScross-sectional196935.0 (30.0, 42.0)14667553.3%81.9%Ogoina D. [43]De.2017–18Nigeriacohort4032.0 [28 d–54.0]319//Aldred B. [44]Ad.2022UScohort39535.0 (30.0, 41.0)394324//Jin Y. [45]De.2023Chinacross-sectional170233.0 ± 7.21702802//Fu L. [46]De.2023Chinacross-sectional11531.0 (27.0, 36.5)11565/93.4%De Sousa D. [47]Ad.2022Portugalcohort58/5825//Guo L. [48]De.2023Chinacohort3933.0 (28.0, 37.0)39200.0%90.0%Vo C. [49]Ad.2022UScohort13037.0 [20.0–58.0]1258015.3%79.2%Núñez I. [50]De.2022Mexicocohort329133.0 (28.0, 39.0)32061939//Kim M. [51]Ad.2020–22UScohort19835.0 (29.8, 43.0)189100//a. Data are presented as case number (n), percentage (%), median (P25, P75), median [min-max], [min-max], or mean ± SD.b. Class. (Classification of Economies); De. (Developing economy); Ad. (Advanced economy); Mul. (Multicenter). Characteristics of included studies. a. Data are presented as case number (n), percentage (%), median (P25, P75), median [min-max], [min-max], or mean ± SD. b. Class. (Classification of Economies); De. (Developing economy); Ad. (Advanced economy); Mul. (Multicenter). A total of 20 studies reported the proportion of participants with AHD in the exposed group, of which 10 had ≥ 90% data completeness. Among these, the AHD proportion was > 5% in 4 studies and was ≤ 5% in 6 studies. Twenty studies reported the viral suppression rates in the exposed group, of which 15 had ≥ 90% data completeness; viral suppression was < 95% in 12 studies and ≥ 95% in 3 studies. Eight studies reported the number of individuals newly diagnosed with HIV during the mpox episode (Table 1 and Table S4). Across the overall study population, prior smallpox vaccination was documented in 14 studies (with > 10% vaccination coverage in 4 studies), and mpox vaccination was reported in 5 studies, predominantly with JYNNEOS (Table S5). Hospitalization rate Primary meta-analysis The hospitalization status of patients was reported in 27 articles. In 7 of these articles, all the patients were hospitalized or none were hospitalized. The specific number of hospitalized patients could not be obtained in 1 article. Finally, the results from 19 articles were included in this meta-analysis. The overall hospitalization rate was 6.43%. Among the exposed group (n = 7,101), the hospitalization rate was 7.82%, whereas it was 4.84% in the control group (n = 6,201). The random-effects model revealed that the hospitalization rate was significantly greater in the exposed group [RR = 1.50, 95% CI (1.17, 1.93)] (Figure 2). Between-study heterogeneity was present (I2 = 76.2%). Forest plot for the effect of HIV coinfection on the hospitalization rate of mpox patients. Exploratory post hoc subgroup analyses (1) Economic development level: In advanced economies, the hospitalization rate was greater in the exposed group [RR = 1.81, 95% CI (1.31, 2.51)]. In developing economies, the difference between groups was not statistically significant [RR = 1.32, 95% CI (0.90, 1.95)] (Figure 2). (2) AHD: Seven articles were included in the subgroup analysis. No differences were found in the subgroup with AHD > 5% [RR = 1.29, 95% CI (0.80, 2.09)] or AHD ≤ 5% [RR = 1.06, 95% CI (0.50, 2.55)] (Figure 3). Forest plot for the effect of HIV coinfection on the hospitalization rate of mpox patients (AHD). Egger’s test indicated no significant publication bias for this outcome (PEgger = 0.177). The funnel plot is shown in Figure S1 (A). No single study had a decisive influence on the overall conclusion, indicating that the findings are robust [Figure S2(A)]. After Benjamini-Hochberg correction for multiple testing, none of the subgroup interactions for hospitalization rate retained statistical significance (Table S7). These findings remain exploratory. Mortality Primary meta-analysis Cases of patient death were reported in 20 articles. No patient deaths were reported in 11 articles, and the results from 9 articles were included in this meta-analysis. The overall mortality rate was 0.58%. The mortality rate was 0.88% in the exposed group (n = 5,328) and 0.16% in the control group (n = 3,858). The random-effects model revealed that the hospitalization rate was significantly greater in the exposed group [RR = 4.54, 95% CI (2.11, 9.77)] (Figure 4). Between-study heterogeneity was present (I2 = 0.0%). Forest plot for the effect of HIV coinfection on mortality in mpox patients. Exploratory post hoc subgroup analyses In advanced economies, the difference between groups was not statistically significant in the exposed group [RR = 2.55, 95% CI (0.18, 35.69)]. In developing economies, mortality was statistically greater in the exposed group [RR = 4.90, 95% CI (2.16, 11.13)] (Figure 4). Fewer than ten studies were available; therefore, publication bias was assessed qualitatively only. The funnel plot showed no obvious asymmetry, although bias could not be ruled out [Figure S1 (B)]. No single study had a decisive influence on the overall conclusion, indicating that the findings are robust [Figure S2 (B)]. Proportion of patients with sexually transmitted pathogen coinfections Primary meta-analysis Eight studies reported syphilis coinfection. The prevalence of syphilis coinfection was significantly greater in the exposed group [RR = 2.08, 95% CI (1.56, 2.77)]. Five studies reported hepatitis C virus (HCV) coinfection, which was significantly more common in the exposed group [RR = 5.48, 95% CI (3.60, 8.34)]. Four studies reported hepatitis B virus (HBV) coinfection, with a significantly greater prevalence in the exposed group [RR = 2.57, 95% CI (1.47, 4.49)]. Six studies reported overall STIs rates, with no significant difference between the exposed and control groups [RR = 1.18, 95% CI (0.80, 1.76)]. The proportions of patients with gonorrhoea, chlamydia, and herpes simplex virus (HSV) coinfections did not significantly differ between the exposed and control groups. Exploratory post hoc subgroup analyses In advanced economies, the difference in syphilis coinfection between groups was not statistically significant [RR = 1.62, 95% CI (0.79, 3.32)], whereas in developing economies, the exposed group had a higher syphilis rate [RR = 2.24, 95% CI (1.60, 3.12)]. For HCV, the exposed group had higher coinfection rates in both advanced [RR = 7.39, 95% CI (3.68, 14.82)] and developing [RR = 4.63, 95% CI (2.73, 7.83)] economies. For HBV, the exposed group in advanced economies had a higher coinfection rate [RR = 3.53, 95% CI (1.44, 8.69)], but no statistically significant difference was found in developing economies [RR = 1.44, 95% CI (0.55, 3.79)]. The detailed results mentioned above are presented in Table 2. Table 2.Meta-analysis of sexually transmitted infection coinfections.STIsArticles No.Sample Size (n)HIV+MPOX (n)MPOX (n)Sub.Pooled RR (95% CI)zPI2 (%)Syphilis8783944143425 2.08 (1.56, 2.77)4.98< 0.00153.8% Ad.1.62 (0.79, 3.32)1.320.188 De.2.24 (1.60, 3.12)4.74< 0.001 Chlamydia7457725172060 1.23 (0.73, 2.09)0.770.43933.8% Ad.1.18 (0.48, 2.90)0.360.721 De.1.35 (0.71, 2.56)0.920.358 Gonorrhea6453524902045 1.50 (0.72, 3.16)1.080.28074.6% Ad.1.60 (0.49, 5.17)0.780.434 De.1.40 (0.75, 2.60)1.050.292 HCV5433324701863 5.48 (3.60, 8.34)7.95< 0.0010.0% Ad.7.39 (3.68, 14.82)5.63< 0.001 De.4.63 (2.73, 7.83)5.71< 0.001 HBV4993514479 2.57 (1.47, 4.49)3.300.001*6.8% Ad.3.53 (1.44, 8.69)2.750.006* De.1.44 (0.55, 3.79)0.750.456 HSV3337419871387 1.16 (0.44, 3.02)0.300.7670.0%All of STIs6344015981842 1.18 (0.80, 1.76)0.830.40576.9%*P value < 0.05; Sub. (Subgroup analysis); De. (Developing economy); Ad. (Advanced economy). Meta-analysis of sexually transmitted infection coinfections. *P value < 0.05; Sub. (Subgroup analysis); De. (Developing economy); Ad. (Advanced economy). Fewer than ten studies were available in all of these subgroups; therefore, publication bias was assessed qualitatively only. The funnel plot showed no obvious asymmetry, although bias could be ruled out [Figure S1 (C–H)]. No single study had a decisive influence on the overall conclusion, indicating that the findings are robust [Figure S2 (C-G)]. Clinical features Primary meta-analysis In this meta-analysis, the differences in 15 clinical features between the exposed and control groups were pooled. The random-effects model revealed that the exposed group had significantly greater incidences of fever [RR = 1.06, 95% CI (1.02, 1.10)], proctitis [RR = 1.50, 95% CI (1.16, 1.96)], malaise [RR = 1.08, 95% CI (1.02, 1.15)], rectal irritation syndrome (RIS) [RR = 1.29, 95% CI (1.11, 1.50)], diarrhoea [RR = 1.78, 95% CI (1.20, 2.63)], skin and soft tissue infection [RR = 2.65, 95% CI (1.33, 5.31)], and pneumonia [RR = 11.00, 95% CI (2.55, 47.35)]; no significant differences were found for the incidence of lymphadenopathy [RR = 0.94, 95% CI (0.86, 1.04)], headache [RR = 1.04, 95% CI (0.99, 1.09)], myalgia [RR = 1.04, 95% CI (0.94, 1.16)], pharyngitis [RR = 1.05, 95% CI (0.83, 1.32)], lower urinary tract symptoms (LUTS) [RR = 0.66, 95% CI (0.36, 1.23)], genital oedema [RR = 0.76, 95% CI (0.40, 1.47)], rhinitis [RR = 0.88, 95% CI (0.21, 3.60)], or tonsillitis [RR = 1.27, 95% CI (0.36, 4.53)]. Exploratory post hoc subgroup analyses (1) Economic development level: In advanced economies, the exposed group had higher rates of rectal irritation syndrome [RR = 1.35, 95% CI (1.04, 1.75)] and skin and soft tissue infection [RR = 2.45, 95% CI (1.17, 5.10)], but these differences were not statistically significant in developing economies. In developing economies, the exposed group had higher rates of fever [RR = 1.10, 95% CI (1.03, 1.17)], proctitis [RR = 1.65, 95% CI (1.23, 2.20)], and malaise [RR = 1.14, 95% CI (1.04, 1.24)], but these differences were not statistically significant in advanced economies (Table 3). Table 3.Meta-analysis of clinical features.Clinical featuresArticles No.Sample Size (n)HIV+MPOX (n)MPOX (n)Sub.Pooled RR (95% CI)zPI2 (%)PEggerFever19938847464642 1.06 (1.02, 1.10)3.210.001*3.4%0.211 Ad.1.04 (0.97, 1.11)1.050.292 De.1.10 (1.03, 1.17)2.750.006* Lymphadenopathy17890345034400 0.94 (0.86, 1.04)1.210.22561.1%0.132 Ad.0.89 (0.74, 1.08)1.200.232 De.0.97 (0.86, 1.09)0.480.634 Headache15882844634365 1.04 (0.99, 1.09)1.450.1460.0%0.258 Ad.1.06 (0.92, 1.22)0.810.416 De.1.03 (0.95, 1.12)0.700.481 Myalgia14832142284093 1.04 (0.94, 1.16)0.730.46426.3%0.825 Ad.1.04 (0.72, 1.50)0.220.829 De.1.02 (0.95, 1.11)0.590.556 Proctitis13851443504164 1.50 (1.16, 1.96)3.040.002*62.2%0.903 Ad.1.20 (0.68, 2.12)0.640.525 De.1.65 (1.23, 2.20)3.370.001* Malaise11808041253955 1.08 (1.02, 1.15)2.560.010*0.0%0.941 Ad.1.04 (0.96, 1.14)0.970.332 De.1.14 (1.04, 1.24)2.860.004* Pharyngitis11265612941362 1.05 (0.83, 1.32)0.410.6850.0%0.478 Ad.1.29 (0.63, 2.65)0.700.483 De.0.89 (0.66, 1.20)0.760.450 $RIS8371514872228 1.29 (1.11, 1.50)3.370.001*14.2%/ Ad.1.35 (1.04, 1.75)2.270.023* De.1.09 (0.70, 1.70)0.390.697 LUTS7733371362 0.66 (0.36, 1.23)1.310.1910.0%/ Ad.0.55 (0.28, 1.11)1.670.096 De.1.92 (0.38, 9.77)0.790.431 Diarrhoea6220410331171 1.78 (1.20, 2.63)2.860.004*0.0%/Genital oedema520269951031 0.76 (0.40, 1.47)0.810.4200.0%/ Ad.0.85 (0.25, 2.84)0.270.788 De.0.73 (0.34, 1.59)0.790.432 #SSTI5703330373 2.65 (1.33, 5.31)2.760.006*0.0%/ Ad.2.45 (1.17, 5.10)2.390.017* De.5.09 (0.63, 41.19)1.520.128 Pneumonia3419137282 11.00 (2.55, 47.35)3.220.001*0.0%/Rhinitis2307125182 0.88 (0.21, 3.60)0.180.8530.0%/Tonsillitis2363114249 1.27 (0.36, 4.53)0.370.70981.9%/*P value < 0.05; $Rectal Irritation Syndrome; #Skin soft tissue infection; Sub. (Subgroup analysis); De. (Developing economy); Ad. (Advanced economy). Meta-analysis of clinical features. *P value < 0.05; $Rectal Irritation Syndrome; #Skin soft tissue infection; Sub. (Subgroup analysis); De. (Developing economy); Ad. (Advanced economy). (2) AHD: The exposed group had higher rates of fever in the subgroup with AHD > 5% [RR = 1.26, 95% CI (1.09, 1.46)] but this finding was not observed in the AHD ≤ 5% subgroup [RR = 1.08, 95% CI (0.98, 1.20)]. The exposed group had higher rates of proctitis in the subgroup with AHD ≤ 5% [RR = 2.01, 95% CI (1.54, 2.63)] but this finding was not observed in the AHD > 5% subgroup [RR = 1.11, 95% CI (0.65, 1.88)]. No statistically significant differences were found for pharyngitis between the two subgroups (Table S6). (3) Viral suppression: The exposed group had higher rates of fever in the subgroup with viral suppression < 95% [RR = 1.11, 95% CI (1.04, 1.18)], but this finding was not observed in the viral suppression ≥ 95% subgroup [RR = 1.00, 95% CI (0.87, 1.17)]. The exposed group had significantly lower rates of lymphadenopathy [RR = 0.90, 95% CI (0.84, 0.97)] and LUTS [RR = 0.49, 95% CI (0.24, 0.99)] in the subgroup with viral suppression < 95%, but this finding was not observed in the viral suppression ≥ 95% subgroup. No statistically significant differences were found for headache, proctitis or genital oedema between the two subgroups (Table S6). Egger’s tests and qualitative assessment revealed no obvious asymmetry. Funnel plots are shown in Figure S1 (I-T). No single study had a decisive influence on the overall conclusions, indicating that the findings are robust [Figure S2 (H-S)]. After Benjamini-Hochberg correction for multiple testing, none of the subgroup interactions for fever, lymphadenopathy, headache, proctitis, pharyngitis, LUTS and genital oedema retained statistical significance (Table S7). These findings remain exploratory. Skin lesion characteristics In this meta-analysis, differences in the location, morphology, and number of skin lesions between the exposed and control groups were pooled by a random-effects model. Location of skin lesions The prevalence of skin lesions located on the genitals did not differ significantly between groups overall [RR = 0.91, 95% CI (0.76, 1.10)]. Subgroup analysis revealed that the differences were lower in the advanced economies [RR = 0.79, 95% CI (0.68, 0.92)] and the viral suppression ≥ 95% [RR = 0.80, 95% CI (0.66, 0.95)] subgroups. No statistically significant differences were found in the developing economies and viral suppression < 95% subgroups. The prevalence of skin lesions located in the perianal region was greater in the exposed group [RR = 1.25, 95% CI (1.09, 1.45)]. Subgroup analysis revealed that this difference was statistically greater in the developing economies [RR = 1.46, 95% CI (1.11, 1.92)] and the viral suppression < 95% [RR = 1.54, 95% CI (1.20, 2.00)] subgroups. No statistically significant differences were found in the advanced economies and viral suppression ≥ 95% subgroups. The overall prevalence of skin lesions located in the anogenital region did not differ significantly between the groups [RR = 1.00, 95% CI (0.83, 1.22)]. The detailed results mentioned above are presented in Table 4 and Table S6. Table 4.Meta-analysis of skin lesions.Skin lesionsArticles No.Sample Size (n)HIV+MPOX (n)MPOX (n)Sub.Pooled RR (95% CI)zPI2(%)PEggerLocation Genital12280913051504 0.91 (0.76, 1.10)0.940.34876.0%0.077 Ad.0.79 (0.68, 0.92)3.050.002* De.1.13 (0.71, 1.79)0.510.608 Perianal11269913081391 1.25 (1.09, 1.45)3.090.002*18.6%0.160 Ad.1.14 (0.98, 1.33)1.710.088 De.1.46 (1.11, 1.92)2.740.006* Anogenital5991504487 1.00 (0.83, 1.22)0.030.97868.1%/Morphology Pustule4564325239 1.08 (0.91, 1.28)0.900.3700.0%/Papule4564325239 0.91 (0.79, 1.05)1.330.1830.0%/Vesicle325515798 1.09 (0.91, 1.32)0.930.3500.0%/Ulceration325515798 0.89 (0.56, 1.41)0.510.6090.0%/Scab3449260189 0.74 (0.43, 1.28)1.080.28278.9%/Macula3523304219 1.16 (0.85, 1.58)0.940.3490.0% No. ≥ 1061450694756 1.06 (0.82, 1.36)0.410.68262.4%/ Ad.0.95 (0.74, 1.22)0.380.707 De.1.91 (1.16, 3.15)2.540.011* *P value < 0.05; Sub. (Subgroup analysis); De. (Developing economy); Ad. (Advanced economy). Meta-analysis of skin lesions. *P value < 0.05; Sub. (Subgroup analysis); De. (Developing economy); Ad. (Advanced economy). After Benjamini-Hochberg correction for multiple testing, none of the subgroup interactions for the prevalence of skin lesions located in the genitals and perianal region retained statistical significance (Table S7). These findings remain exploratory. Number and morphology of skin lesions The proportion of patients with ≥ 10 skin lesions was not significantly different between the two groups [RR = 1.06, 95% CI (0.82, 1.36)]. Subgroup analysis revealed that this difference was greater in the developing economies subgroup [RR = 1.91, 95% CI (1.16, 3.15)]. The morphology of the skin lesions (vesicle, pustule, ulceration, papule, macula, scab) did not significantly differ between the two groups (Table 4). Egger’s tests and qualitative assessment revealed no obvious asymmetry. Funnel plots are shown in Figure S1 (U-Z). No single study had a decisive influence on the overall conclusion, indicating that the findings are robust [Figure S2 (T-W)]. Blood test results In this meta-analysis, differences in 16 blood parameters between the exposed and control groups were pooled. The exposed group had significantly lower levels of albumin [SMD = −0.52, 95% CI (−0.94, −0.11)], calcium [SMD = −0.56, 95% CI (−0.90, −0.21)] and haemoglobin [SMD = −0.61, 95% CI (−0.96, −0.27)] and significantly higher levels of creatine kinase isoenzyme-MB (CK-MB) [SMD = 0.52, 95% CI (0.10, 0.93)]. No significant differences in white blood cell counts, C-reactive protein (CRP) levels, lymphocyte counts, platelet counts, alanine aminotransferase levels, lactate dehydrogenase levels, neutrophil counts, monocyte counts, aspartate aminotransferase levels, creatinine levels, creatine kinase levels or D-dimer levels were detected. Owing to the limited number of studies, subgroup analysis was not performed for blood test results (Table 5). Table 5.Meta-analysis of blood test results (SMD).Blood routine examinationArticles No.Sample size (n)HIV + MPOX (n)MPOX (n)SMD (95% CI)zPI2(%)White blood cell count52731331400.03 (−0.22, 0.27)0.210.8360.0%C-reactive protein53331841490.30 (−0.10, 0.70)1.490.13666.5%Lymphocyte count41799089−0.16 (−0.50, 0.18)0.940.34720.3%Platelet count31386969−0.15 (−0.62, 0.31)0.640.51946.0%Alanine aminotransferase31919299−0.10 (−0.48, 0.28)0.510.60839.9%Lactate dehydrogenase319712077−0.12 (−1.08, 1.33)0.200.84193.2%Neutrophil count28548370.26 (−0.40, 0.92)0.770.43856.6%Monocyte count28548370.14 (−0.30, 0.57)0.610.5410.0%Albumin2974948−0.52 (−0.94, −0.11)2.480.013*0.0%Aspartate aminotransferase2974948−0.35 (−0.95, 0.25)1.150.24952.4%Creatinine214398450.27 (−0.78, 1.32)0.510.61286.9%Creatine kinase2984949−0.22 (−0.62, 0.19)1.050.2960.0%CK-MB29849490.52 (0.10, 0.93)2.460.014*0.0%Calcium21549361−0.56 (−0.90, −0.21)3.160.002*0.0%Haemoglobin21549361−0.61 (−0.96, −0.27)3.470.001*0.0%D-dimer213564710.22 (−0.12, 0.56)1.280.2020.0%*P value < 0.05. Meta-analysis of blood test results (SMD). *P value < 0.05. Discussion The results of this meta-analysis indicate that HIV coinfection leads to significantly increased hospitalization rates and mortality and to increased rates of coinfection with sexually transmitted pathogens such as syphilis, HBV, and HCV in mpox patients. Furthermore, the probability of rectal and anal involvement and the occurrence of complications are also significantly elevated. A meta-analysis by Amira Mohamed Taha et al. revealed higher mortality in mpox patients with HIV coinfection, which is consistent with our findings, but these authors reported no significant difference in hospitalization rates [52]. This discrepancy may partly reflect differences in eligibility criteria. In our analysis, we excluded studies that enrolled only hospitalized patients or no patients with hospitalization events, because such studies define the outcome by design rather than observing it as a naturally occurring event, which could introduce selection bias and distort the pooled estimate of hospitalization risk attributable to HIV infection. Our results suggest that mpox patients coinfected with HIV have a higher probability of requiring hospitalization, which is consistent with the findings of a previous report [53]. Interestingly, subgroup analysis revealed that the exposed group within advanced economies had higher hospitalization rates but lower mortality rates, whereas the opposite pattern was observed in developing economies. This may be related to three factors. First, regional disparities in the HIV care continuum may play a critical role. In advanced economies, especially in Western Europe and North America, higher coverage of HIV diagnosis, sustained antiretroviral therapy (ART), and long-term virological monitoring likely contribute to a lower prevalence of both incomplete viral suppression and AHD among PLWH [54]. However, this relationship is not absolute: higher national economic capacity does not invariably translate into superior HIV care outcomes, as evidenced by the substantial heterogeneity in ART coverage and viral suppression rates among countries with comparable income levels [54,55]. Moreover, within countries, racial composition, socioeconomic development, and healthcare accessibility are closely intertwined, collectively influencing HIV care outcomes and further complicating the observed association [54]. Second, differential access to diagnostics and healthcare seeking behaviour likely introduces systematic ascertainment bias. In advanced economies, greater health literacy, better healthcare access, and more sensitive laboratory surveillance systems facilitate the identification of milder mpox cases that might otherwise go undetected [56]. Conversely, in developing economies where mpox is endemic, particularly in several African regions, laboratory testing capacity remains severely constrained, with only a fraction of suspected mpox cases receiving confirmatory diagnosis [57]. This under detection of mild or nonhospitalized cases may artificially inflate apparent severity and mortality metrics, thereby distorting the observed rates of hospitalization and mortality. Third, the geographic distribution of MPXV clades represents an important virological confounder [58]. Although the majority of the studies included in our analysis were conducted during the 2022–2023 global outbreak, predominantly driven by clade IIb, we cannot exclude the possibility that interclade heterogeneity contributed to the observed regional differences in clinical outcomes, especially given that clade information was reported in only a small minority of primary studies [59]. Notably, we did not observe a significant association between AHD status and hospitalization rates in our post hoc subgroup analyses. This null finding may reflect the limited number of studies available for inclusion. Consistent with these observations, some studies have reported that the CD4+ T-cell count is not an independent predictor of adverse mpox outcomes according to multivariable analyses [44]. This raises the hypothesis that incomplete HIV viral suppression, rather than a low CD4+ T-cell count alone, may be a more clinically relevant determinant of mpox severity [60]. Nevertheless, given the limited granularity of the primary data. Our findings might be interpreted as exploratory and hypothesis generating. They are intended to inform the design of future large-scale prospective studies and should not be regarded as confirmatory. No specific antiviral drugs with proven efficacy against MPXV infection are currently available [61]. Notably, a recent randomized controlled trial demonstrated no evidence that tecovirimat therapy shortened the time to clinical resolution, reduced pain, or increased viral clearance among adults with clade II mpox [62]. Although some countries and regions have incorporated drugs such as tecovirimat into their treatment protocols for MPXV, their effectiveness remains suboptimal [63,64]. The available evidence has demonstrated that both smallpox and mpox vaccines significantly modify the clinical presentation of mpox, even though they do not confer complete protection against infection [65,66]. Notably, this attenuation of disease severity extends to people with HIV, including those with low CD4 T-cell counts, in whom preexposure vaccination markedly reduces the risk of hospitalization and symptom severity despite modestly diminished effectiveness against infection [67,68]. Despite this evidence, the scarcity of vaccination data in the primary studies precluded a formal subgroup analysis on this factor. In the absence of specific therapies, key measures to reduce the risk of hospitalization and death include increasing disease awareness, strengthening supportive care for HIV coinfected patients and promoting vaccination in high-risk groups [69]. We found that more than 90% of the mpox patients were male, predominantly young and sexually active males, and more than half were living with HIV, which is consistent with the majority of related reports [11]. Sexual contact, particularly among MSM, is a major transmission route for MPXV [70]. Concurrent infection with other sexually transmitted pathogens is possible during MPXV infection. Some studies have suggested that the proportion of mpox patients coinfected with HIV who also have syphilis is significantly greater than that among those without HIV, and our meta-analysis corroborates these observations, revealing a significantly greater proportion of patients with syphilis coinfection [23,25,35,40]. However, post hoc subgroup analysis revealed that this difference was driven primarily by studies from developing economies, with no significant difference observed in advanced economies. We speculate that these observations may be related to regional differences in condom use patterns among MSM. Current evidence indicates that, unlike other sexually transmitted infections, MPXV can also be transmitted through intimate skin-to-skin contact, and the protective effect of condoms against MPXV infection is therefore inherently limited [71]. Nevertheless, condoms remain a cornerstone of prevention for other STIs, such as syphilis. Suboptimal condom use is relatively common among MSM and represents an established risk factor for HIV and other sexually transmitted pathogens, which may partly explain the greater rates of STIs, such as syphilis, observed in the exposed group from developing economies [72]. Condom use behaviours among MSM are influenced by multiple factors, including economic status, HIV/STIs knowledge, stigma and discrimination, and condom accessibility [73,74]. It must be acknowledged that this speculation has inherent limitations: The regional economic development level is not fully equivalent to condom use behaviours. Although direct behavioural data among mpox patients are lacking, these findings suggest that efforts to promote consistent condom use for STIs prevention in developing economies remain warranted [75]. Unlike the pattern observed for syphilis, the difference in the incidence of HBV coinfection between the exposed and control groups was primarily observed in studies from advanced economies. This may be related to HBV vaccine coverage rates in specific age groups and regions, particularly in developing economies where immunization programmes have led to a sharp decline in the prevalence of hepatitis B infection [76]. It is also possible that the differing primary transmission routes of HBV across regions contribute to this pattern, with mother-to-child transmission being predominant in the African and Western Pacific regions rather than sexual transmission [77]. Furthermore, the epidemiology and dynamic changes associated with chronic HBV infection are complex and vary significantly across countries and regions and are closely linked to public health policies and development [78]. The higher prevalence of HCV coinfection in the exposed group was consistent across both the advanced and developing economy subgroups, which aligns with the established view that high-risk populations for HCV infection include MSM and people living with HIV [79]. However, it should be noted that all subgroup analyses presented here were post hoc and exploratory; these observations should therefore be interpreted as hypothesis generating rather than confirmatory. The present meta-analysis revealed higher proportions of patients who presented with fever and malaise in the exposed group. Post hoc subgroup analyses indicated that the difference in fever was observed primarily in developing economies and in the subgroup with viral suppression < 95% and, separately, in the subgroup with AHD > 5%, which may be related to suboptimal HIV viral control and severe immunosuppression. However, these are post hoc exploratory findings that require validation in prospective cohort studies. A noteworthy observation is that the incidence of lymphadenopathy in the exposed group was paradoxically lower in the subgroup with viral suppression < 95%. We speculate that these counterintuitive findings may be attributable to HIV-related immune deficiency modulating the host inflammatory response pattern or to lymph node architectural fibrosis associated with advanced HIV infection, the latter of which may impair the capacity of lymphoid tissue to respond to viral infection [80]. Like the pattern observed for lymphadenopathy, the exposed group exhibited a lower frequency of lower urinary tract symptoms within the viral suppression < 95% subgroup. However, we suspect that these findings may be attributable to inconsistencies in the composite reporting of symptoms, as the majority of the included studies documented only external genital lesions without providing specific details on lower urinary tract symptoms. Nevertheless, the accuracy and clinical significance of these speculations require further investigation. The proportion of patients with proctitis or rectal irritation syndrome was greater in the exposed group. Although the magnitude and statistical significance of this difference varied across economic subgroups, possibly reflecting differences in diagnostic criteria, screening practices, or patient reporting bias, the direction of the effect consistently pointed to greater rectal and anal involvement in the exposed group. Furthermore, post hoc subgroup analysis revealed a higher incidence of proctitis in the exposed group within the AHD ≤ 5% subgroup. Given these unexpected findings, we speculate that in the subgroup with a lower proportion of AHD, lesions may be confined to the rectum rather than involving the entire intestinal tract. If this speculation holds true, patients with a higher proportion of AHD would be more prone to developing extensive intestinal involvement, which may partly explain the higher incidence of diarrhoea observed in the exposed group [81]. In any case, intestinal involvement, particularly among patients with suboptimal HIV viral suppression or AHD, warrants greater clinical attention. Notably, the exposed group had a significantly higher rate of pneumonia. Models developed by Thanaphon Namporn et al. demonstrate that MPXV can be transmitted via the respiratory route, further complicating containment efforts [82,83]. This observation underscores the need for greater attention to the impact of MPXV infection on organs and systems beyond the skin in immunocompromised patients [84]. Furthermore, although reports concerning the neurological pathogenicity of orthopoxviruses are limited, the risk of neurological complications from MPXV infection should not be overlooked [85,86]. We also observed that the proportion of patients with skin and soft tissue infections was significantly greater in the exposed group than in the control group. In the subgroup of developing economies, however, no significant difference was detected between the exposed and control groups, which may be attributable to inconsistencies in the definitions and scope of skin and soft tissue infections across the included studies. Importantly, all subgroup analyses presented above are post hoc and exploratory in nature; these observations should therefore be interpreted as hypothesis generating only, and the true underlying causes require further investigation in large-scale, real-world studies. The MPXV viral load in rectal and lesion swabs is significantly greater than that in oropharyngeal swabs and urine samples [87]. The clinical manifestations and skin lesion patterns observed in this meta-analysis further enrich our understanding of the clinical presentation and lesion distribution of mpox. Although the overall analysis revealed no significant difference in the proportion of patients with genital lesions between the exposed and control groups, post hoc subgroup analyses indicated that this proportion was significantly lower in the exposed group within advanced economies and in the subgroup with HIV viral suppression ≥ 95%. In contrast, the proportion of perianal lesions was greater in the exposed group, a difference driven primarily by developing economies and the subgroup with viral suppression < 95%. Moreover, although the overall number of skin lesions did not differ significantly between the exposed and control groups, post hoc subgroup analyses indicated that the number of lesions was significantly greater in the exposed group within developing economies. Taken together, these observations suggest that while the viral load at the MPXV inoculation site is undoubtedly an important determinant of local pathology, the ultimate severity of skin lesions caused by high MPXV loads may depend substantially on host immune status: the immunodeficiency state associated with high HIV viral load may compromise local containment of MPXV replication, leading to more severe and more readily disseminated skin lesions. Of further concern, some of the included studies reported cases of incident HIV infection concurrent with a mpox diagnosis. Moreover, the existing evidence indicates that ART-naive PLWH with MPXV coinfection consistently experience more severe disease, a longer disease duration, and higher mortality [9,88]. These patients lie at the most vulnerable end of the immune status spectrum described above, yet relevant reports remain scarce. We therefore call for future studies to prioritize the reporting and stratified analysis of cases involving incident HIV infection concurrent with MPXV to better characterize the clinical features and prognosis of this high-risk population. Given that the above are all post hoc exploratory subgroup analyses, these findings should be interpreted as hypothesis generating and not as confirmatory conclusions. The blood levels of CK-MB were significantly greater in the exposed group than in the control group, possibly indicating some degree of myocardial injury. Conversely, the levels of albumin, calcium, and haemoglobin were significantly lower in the exposed group. Owing to the limited number of studies, determining the clinical significance of these differences is difficult. Furthermore, whether these differences are solely due to HIV infection or exacerbated by MPXV infection requires further investigation. However, malnutrition and preexisting organ damage in people living with HIV might be baseline factors contributing to severe disease and death following MPXV infection [89,90]. This study has several limitations that should be noted. First, although post hoc exploratory subgroup analyses were conducted in this study, the lack of individual-level data on HIV viral load, peripheral blood CD4+ T-cell counts, and ART duration, regimen, and coverage precludes definitive conclusions. This limitation is particularly relevant given that HIV serostatus alone may serve only as a proxy for the underlying degree of immune deficiency. Second, the meta-analysis was conducted at the aggregate level, which precludes adjustment for individual-level covariates. Unmeasured confounding may therefore have biased the pooled effect estimates. Key confounders, including ART use and adherence, prior smallpox or mpox vaccination history, and sexual network characteristics, could not be accounted for, and their distribution likely differs between the exposed and control groups. Although sensitivity analyses indicated that no single study had a decisive influence on the principal pooled results, these analyses cannot address bias arising from unmeasured confounders. Given these limitations, residual confounding cannot be excluded. Third, we conducted post hoc subgroup analyses across all factors applied to multiple outcomes, producing a large number of independent statistical tests. To account for multiplicity, the Benjamini-Hochberg FDR procedure was applied within each outcome family. After correction, none of the subgroup interactions retained statistical significance. Although we have consistently labelled these analyses as exploratory and have avoided drawing confirmatory conclusions, the possibility of false-positive signals in uncorrected analyses remains. Fourth, pooled data on the MPXV viral load and the detailed grading of skin lesion counts were lacking because of insufficient reported data in the included literature. High MPXV viral load and numerous skin lesions are key risk factors for prolonged disease duration [91]. MPXV may exploit the immune environment created by HIV infection, leading to reduced viral clearance capacity and prolonged viral shedding, potentially the main reason for severe disease and death in the exposed group [5]. However, this hypothesis could not be directly tested in this review. Fifth, the lack of analyses based on the MPXV clade represents another limitation. Whether the impact of HIV infection on viral load and skin lesion characteristics differs between patients infected with different MPXV clades requires further exploration. Sixth, the present study was unable to conduct subgroup analyses on paediatric and pregnant mpox patients. In mpox endemic regions, particularly in Africa, data on infection in these individuals remain fragmented and limited [92–94]. Future studies should prioritize a deeper understanding of the clinical characteristics and outcomes in these vulnerable groups, particularly regarding HIV coinfection, mortality rates, and adverse clinical outcomes. Seventh, the mortality outcome was based on only nine studies, and publication bias could be assessed only qualitatively. Additionally, our search was restricted to English-language publications, which may have excluded relevant reports from high-burden regions in Africa and Latin America published in other languages or as grey literature. More broadly, for all outcomes with fewer than ten studies, formal statistical tests for publication bias were not performed, and the possibility of unpublished null findings cannot be excluded. Future studies investigating mpox in HIV coinfected populations should prioritize the systematic collection and reporting of individual-level data on CD4+ T-cell count, HIV viral load, and ART status to enable more definitive stratified analyses. In addition, systematic documentation of smallpox and mpox vaccination history, as well as MPXV clade information, is essential, as both vaccination status and viral clade may significantly influence clinical outcomes, and their absence precluded formal subgroup analyses in this review. Prospective cohort studies with prespecified subgroup comparisons by HIV viral suppression, AHD status, vaccination history, and MPXV clade are needed to validate the exploratory findings of this review. Furthermore, dedicated reporting of cases involving incident HIV infection concurrent with a mpox diagnosis is essential to better define the clinical trajectory and optimal management of this uniquely vulnerable population. In conclusion, this meta-analysis demonstrates that mpox patients with HIV coinfection experience significantly higher rates of hospitalization, mortality, and coinfection with sexually transmitted pathogens, as well as more severe clinical manifestations and a greater overall burden of complications. Of particular concern, patients with an unsuppressed HIV viral load, including those who are ART-naive and those newly diagnosed with HIV at the time of mpox presentation, may face a disproportionately elevated risk of severe illness and death, even if they constitute a minority of all mpox cases. This vulnerability likely reflects impaired viral clearance and prolonged viral shedding in the context of HIV-related immunosuppression, a hypothesis that warrants direct investigation in future studies. Nevertheless, given the exploratory and post hoc nature of the subgroup analyses and the lack of individual-level data in this review, these findings should be interpreted with caution, and definitive causal inferences require validation in prospective cohort studies. Future research should prioritize the separate, stratified reporting of these immunologically vulnerable subgroups. Furthermore, strengthening outbreak surveillance, systematically documenting smallpox and mpox vaccination history, and ensuring equitable vaccine access for high-risk populations remain essential strategies for mitigating the public health threat posed by MPXV. In the absence of effective antiviral agents that specifically target MPXV, determining the optimal timing for ART initiation, particularly in patients with newly diagnosed HIV during a mpox episode, and optimizing supportive care protocols are important for reducing mpox-related mortality and improving outcomes in severe cases. Supplementary Material 260713_Supplementary_Figures_and_Tables_Revised-clean.docx